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This document summarizes the rationale, equipment, protocol, assay, internal quality control, data 
cleaning, external quality control, and procedures for the measurement and classification of kidney 
(renal) function at the Wave V home exam.  Whenever possible, data collection and methods in Wave V 
mirrored those of Wave IV to ensure comparability of data between waves, although important inter-
Wave differences exist and are grey highlighted herein. This document is one in a set of Wave V user 
guides. User guides are also available to describe protocols for the following biological measures at 
Wave V: 
 Anthropometrics 
 Cardiovascular Measures 
 Medication Use – Home Exam 
 Baroreflex Sensitivity, & Hemodynamic Recovery 
 Glucose Homeostasis 





This research uses data from Add Health, a program project directed by Kathleen Mullan Harris and 
designed by J. Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris at the University of North 
Carolina at Chapel Hill, and funded by grant P01-HD31921 from the Eunice Kennedy Shriver National 
Institute of Child Health and Human Development, with cooperative funding from 23 other federal 
agencies and foundations. We gratefully acknowledge Carolyn Halpern, Nancy Dole, Joyce Tabor, and 
Sarah Dean for their dedication to the quality of the Add Health data in this document. Information on 





Citations of this Add Health User Guide should use the following format: 
Whitsel EA, Angel R, O’Hara R, Qu L, Carrier K, Harris K. Add Health Wave V Documentation: Renal 
Function, 2020; Available from: https://doi.org/insert doi here  
  
Add Health is a program project directed by Kathleen Mullan Harris and designed by J. Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris at the 
University of North Carolina at Chapel Hill, and funded by grant P01-HD31921 from the Eunice Kennedy Shriver National Institute of Child Health and 
Human Development, with cooperative funding from 23 other federal agencies and foundations. Information on how to obtain the Add Health data files is 
available on the Add Health website (http://www.cpc.unc.edu/addhealth). 
3 | P a g e   
Table of Contents 
1. Introduction .......................................................................................................................................... 4 
2. General Overview of Data Collection ................................................................................................... 4 
3. Blood Collection .................................................................................................................................... 5 
3.1 Rationale ......................................................................................................................................... 5 
3.2 Equipment ....................................................................................................................................... 5 
3.3 General Protocol ............................................................................................................................. 6 
3.3.1 Blood Collection ........................................................................................................................... 6 
3.3.2 Blood Processing .......................................................................................................................... 9 
3.3.3 Shipment of Samples ................................................................................................................. 10 
3.3.4 Receipt of Samples at LCBR ........................................................................................................ 11 
4. Assay and Internal Quality Control ..................................................................................................... 11 
4.1 Creatinine [H5CREAT] ................................................................................................................... 11 
4.1.1 Rationale .................................................................................................................................... 11 
4.1.2 Colorimetric Assay Protocol ....................................................................................................... 11 
4.1.3 Internal Quality Control ............................................................................................................. 13 
4.2 Cystatin C [H5CYSC] ...................................................................................................................... 14 
4.2.1 Rationale .................................................................................................................................... 14 
4.2.2 Colorimetric Assay Protocol ....................................................................................................... 14 
4.2.3 Internal Quality Control ............................................................................................................. 15 
4.2.4 Standardization .......................................................................................................................... 15 
4.2.5 Inter-conversion of Pre- & Post-IFCC Standardization of Cystatin C Concentrations ................ 15 
5. External Quality Control ..................................................................................................................... 16 
5.1 Reliability ....................................................................................................................................... 16 
6. Constructed Measures ........................................................................................................................ 17 
6.1 Estimated Glomerular Filtration Rate (eGFR) According to NIDDK CKD-EPI Guidelines 
[H5GFRCRE; H5GFRCYC; H5GFRCC] ................................................................................................... 17 
6.2 Classifications of eGFR According to KDIGO Guidelines [H5CGFRKR; H5CGFRKY; H5CGFRKC] ... 18 
6.3 Clinical Classifications of eGFR 6.3 [H5CGFRCR; H5CGFRCY; H5CGFRCC] .................................... 18 
7. The Renal Function Data File (brenal5.xpt) ........................................................................................ 19 
7.1. Structure ...................................................................................................................................... 19 
7.2. Contents ....................................................................................................................................... 19 
8. References .......................................................................................................................................... 20 
 
Add Health is a program project directed by Kathleen Mullan Harris and designed by J. Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris at the 
University of North Carolina at Chapel Hill, and funded by grant P01-HD31921 from the Eunice Kennedy Shriver National Institute of Child Health and 
Human Development, with cooperative funding from 23 other federal agencies and foundations. Information on how to obtain the Add Health data files is 
available on the Add Health website (http://www.cpc.unc.edu/addhealth). 
4 | P a g e   
 
1. Introduction 
Renal function was not measured at Wave IV, but was measured at Wave V. Briefly, blood was collected 
by field examiners (FEs) certified in phlebotomy, chilled at 4°C during the remainder of the home exam, 
centrifuged immediately afterward, aliquoted into transport tubes, and then sent overnight to a 
laboratory for assay. 
 
Assayed Renal Biomarkers: 
 
• Creatinine (mg/dL) 
• Cystatin C (mg/L) 
 
Moreover, the restricted use Add Health Wave V data includes nine constructed measures designed to 
facilitate analysis and interpretation of renal function: 
 
Estimated Glomerular Filtration Rate (eGFR, ml/min/1.73 m2) According to NIDDK CKD-EPI Guidelines.1 
 
• Based on creatinine  
• Based on cystatin C  
• Based on both creatinine and cystatin C 
 
Classifications of eGFR According to KDIGO Guidelines2  
• Based on creatinine  
• Based on cystatin C 
• Based on both creatinine and cystatin C 
 
Clinical Classifications of eGFR 
• Based on creatinine 
• Based on cystatin C 
• Based on both creatinine and cystatin C 
 
2. General Overview of Data Collection 
All Wave V venous blood samples were collected during home exams performed by FEs from two Add 
Health data collection partners: Examination Management Services, Inc. (2016–2017) and Hooper 
Holmes, Inc. (2018–2019). All FEs were trained and certified using a custom program specific to the Add 
Health protocol. FEs used a 7” Samsung Galaxy Tab 4 tablet to record and transmit data. An Add Health 
data collection application (Open Data Kit or ODK) installed on the tablet guided the FEs through the 
home exam protocol. In addition, FEs received a series of job aids, both on paper and on the tablet, to 
serve as quick reference guides when completing the protocol. Each tablet also contained an in-depth 
Add Health training manual that could be accessed at any time. 
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FEs conducted home exams among previously consented respondents. All FEs were phlebotomy-
certified and had at least two years of experience collecting venous blood. Before home exams, FEs 
were sent a Visit Supply Kit that included a box for shipping blood to the lab and a Blood Collection Kit 
containing most required materials for the blood collection. FEs supplied additional materials, as needed 
(see section 3.2). Protocols for blood collection were dictated to FEs by the handheld 7” Samsung tablet 
used during all home exams. The tablet gave step-by-step directions for the blood collection and 
required FEs to enter information about the blood draw for each respondent. All respondents had the 
option to decline part or all of the blood draw, although declining did not affect their ability to 
participate in the rest of the home exam.  Overall, 91.8% of the respondents agreed to and completed 
the blood draw.  Of the remainder, 6.5% refused, 1.3% agreed but the blood draw was unsuccessful, and 
< 1% had exams terminated before the blood draw (see the blood draw status variable H5BLOOD in the 
bdemo5 data set and codebook). 
 
Blood collection was the last step in the home exam. Afterwards, all collection tubes were inverted 8-10 
times to distribute the blood and contents of the tubes and then chilled at 4⁰ C (on ice or frozen cold 
packs) for up to two hours. Subsequent processing involved centrifuging specific tubes then aliquoting 
serum and plasma into color-coded transport tubes pre-labelled with unique barcode identifiers linking 
the blood to a particular respondent. Then the transport tubes were packaged in a Styrofoam Box with 
frozen cold packs and shipped overnight via FedEx to the Laboratory for Clinical Biochemistry Research 
(LCBR) at the University of Vermont. Overnight shipment enabled receipt by LCBR before 10:30 am the 
next morning.  Upon receipt, LCBR documented the arrival of the transport tubes, evaluated their 
condition, processed them, and either assayed the specimens or aliquoted and archived them in -80°C 
freezers.   
 




Venous blood was collected to provide Add Health with the biological specimens necessary to assay and 
interpret a pre-specified panel of metabolic, hematologic, inflammatory, immune, and renal biomarkers, 
including the measures of renal function described herein. It also was collected to establish an archive of 





Before exams, FEs were shipped a Visit Supply Kit (Exhibit 1) including (1) a cardboard Shipping Box with 
an inner Styrofoam Box and two cold packs for shipping collected samples to LCBR, (2) a large Tyvek 
envelope in which to ship the Shipping Box, and (3) a Blood Collection Kit for collecting blood.  The Blood 
Collection Kit contained: 
 
• Biohazard-labelled Ziploc bag 
• Latex-free gloves 
• 2”x2” gauze 
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• Latex-free, Band-Aid type adhesive dressings 
• Latex-free, strap tourniquet 
• Alcohol prep pads, disposable pipets 
• Single-use vacutainer (blood collection) tube holder 
• 21-gauge Eclipse straight needle 
• 21-gauge butterfly needle 
• (3) disposable 3 ml graduated transfer pipets 
• (2) 8.5 ml serum separation transport (SST) vacutainer tubes 
• (1) 6 ml sodium fluoride/potassium oxalate (NaFl/KOx)-containing vacutainer tube, if needed for 
the glucose sub-study (see Section 4.1.2.1) 
• (1) 3- or 4- ml potassium ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tube 
• (1) 10 ml EDTA-containing vacutainer tube 
• (1) 10 ml PAXgene vacutainer tube (containing 7.5 ml of preservative) 
• (4) 10 ml transport tubes with color coded caps  
• Extra barcode labels 
 
BD Biosciences (San Jose, CA) supplied all the vacutainer and transport tubes. As of February 2018, their 
3 ml EDTA vacutainer tube (Cat #367835) was no longer available, so Add Health switched to the 4 ml 
EDTA vacutainer tube (Cat #367844). 
 
 
Exhibit 1. Visit Supply and Blood Collection Kits 
 
FEs were responsible for providing ancillary materials for each home exam, including but not limited to a 
chux-type absorbent under pad, a sharps container, and a cooler with cold packs for keeping samples 
cold before packaging and shipping them to LCBR. 
 
3.3 General Protocol 
 
3.3.1 Blood Collection 
 
The blood draw was performed as the final stage of the home exam following collection of 
anthropometric, cardiovascular, and medication information. After confirming respondents were 
comfortable giving blood, respondents were asked to either sit or recline at their discretion. They also 
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were asked if they had problems in the past with blood collection such as fainting, bleeding, or hard-to-
find veins. FEs were instructed to ensure the blood collection area was private, uncluttered, and fully 
prepared before beginning the blood draw. Preparation involved placing the chux pad, organizing the 
vacutainer tubes/supplies, preparing the cooler to accept the blood samples, and scanning the barcode 
located on the outside of the Blood Collection Kit. Scanning it automatically captured a unique, eight-
digit code, thereby linking the respondent to the transport tubes / labels within it, the corresponding 
ODK questionnaire data, and ultimately to LCBR results. 
 
Following standard phlebotomy protocols, FEs asked respondents to identify an arm for collecting blood, 
applied the tourniquet to that arm, and identified a vein in the antecubital fossa for venipuncture. If no 
vein appeared suitable, FEs asked to try the opposite arm. Unless respondents had objections, 
venipuncture was performed on the best potential vein and whole blood was collected, as summarized 
below: 
 
• Put on nitrile gloves. 
• Have the respondent extend his/her arm on the protective pad, palm up and straight at the 
elbow. 
• Inspect the arm. Do not draw blood from an arm that has a rash, open sore, is swollen or shows 
signs of a recent venipuncture or hematoma. Do not draw blood from an arm that contains an 
arterial access such as a fistula or shunt.  
• Apply the tourniquet several inches above the elbow and palpate for a suitable vein.  
• Select a vein that is palpable and well-fixed to surrounding tissue. 
• Open the needle assembly unit and attach it to the vacutainer holder.  
• Ask the respondent to make a tight fist. Cleanse the area with an alcohol wipe using a circular 
motion and allow the area to air dry. 
• Remove the cover from the needle. 
• The vein should be fixed or held taut during the puncture. Push the needle firmly and 
deliberately into the vein. When firmly in the vein, blood appears in the tubing of the needle 
assembly past the end of the needle. 
• Attach the needle holder and quickly push the first vacutainer tube (ordered in Exhibit 2, below) 
onto the needle in the holder, puncturing the center of the stopper.  
• Release the tourniquet after the flow is established or if the respondent becomes 
uncomfortable. The respondent may open his/her fist once blood flow is established. 
• When the first vacutainer tube is filled to capacity, remove it from the holder and place the next 
vacutainer tube in the holder. 
• Gently invert each vacutainer tube 8-10 times immediately upon removing each one and while 
filling the next one. Repeat until all the desired vacutainer tubes are filled. 
• Place all filled vacutainer tubes directly into a cooler with ice or ice packs. 
• When the last vacutainer tube is filled, remove the tourniquet, carefully withdraw the needle, 
and cover the venipuncture site with a sterile gauze pad. 
• Never apply pressure to the gauze until the needle is clear of the puncture site and away from 
the arm. 
• Have the respondent hold the gauze pad with mild pressure and sit quietly for a few minutes.  
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• Slide the needle safety guard forward to prevent an accidental needle stick. Discard the entire 
used needle assembly in a sharps container.  
• Check the venipuncture site. If it is adequately clotted, remove the gauze and apply a bandage. 
If after a few minutes, bleeding continues keep direct pressure on the site for 5 minutes. 
• Encourage the respondent to sit quietly for a few minutes. Due to a fasting blood draw 
encourage the respondent to eat a snack if needed. 
 
When the first attempt at blood collection was unsuccessful, FEs were allowed to ask to draw blood 
from the opposite arm. However, no more than two blood collection attempts were permitted. 
Moreover, only the antecubital fossa was acceptable for blood draw. FEs were not allowed to collect 
blood from any other sites, such as the back of the hand. 
 
Either 5 or 6 tubes of blood were collected per respondent, depending on eligibility for a separate 
glucose sub-study (see Measures of Glucose Homeostasis User Guide, Section 4.1.2.1). Collection order, 
tube type, and processing information are listed below (Exhibit 2). 
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1 8.5 ml SST Yes Serum Discarded 
Assays: glucose, total 
cholesterol, high- & low- 
density lipoprotein-
cholesterol, triglycerides, 
high sensitivity C reactive 
protein, creatinine & 
cystatin C 
2 10 ml EDTA Yes Plasma 
RBC/buffy 
coat 
Archival: for future use 
3 
3 or 4 ml 
EDTA 
No N/A N/A 
Assay: hemoglobin A1c 
Archival: for future use 








No N/A N/A Archival: for future use 
 
Exhibit 2. Tubes of Blood Collected 
 
3.3.2 Blood Processing 
 
The venous blood draw concluded the home exam. After cleaning up all supplies and equipment, FEs left 
the exam sites and were allowed a maximum of two hours before processing the blood which was 
chilled at 4⁰ C (on ice or frozen cold packs) in the interim. 
 
All FEs centrifuged specific blood collection tubes, including the 8.5 ml SST, 10 ml EDTA, and when 
collected, the 6 ml NaFl/KOx vacutainer tubes. The 3-4 ml EDTA vacutainer tube used for the HbA1c 
assay was not centrifuged. FEs centrifuged tubes for ≥ 10 min at ≥ 1300 g, depending on the capabilities 
of their centrifuge. After centrifugation, FEs used the graduated transfer pipettes included in the Blood 
Collection Kit to aliquot serum from the SST and (separately, when collected) plasma from the NaFl/KOx 
vacutainer tubes into 10 ml, round bottom, skirted transport tubes (BD Biosciences, NJ). FEs aliquoted as 
much supernatant as possible into the transport tubes but avoided disturbing the precipitate layer. A 
red cap identified transport tubes containing serum from the SST vacutainer tubes, a blue cap identified 
transport tubes containing plasma from the 10 ml EDTA vacutainer tube, and a white cap identified the 
transport tube containing plasma from the Na/Fl/KOx tube. Transport tubes were chilled at 4⁰ C (on ice 
or frozen cold packs) until packaged for shipment to LCBR. Exhibit 3 demonstrates the complete blood 
processing protocol. 
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Exhibit 3. Blood Processing Protocol 
 
After processing the blood, FEs took a loose barcode label provided in the Blood Collection Kit and 
affixed it to a paper manifest designed to accompany the transport tubes to LCBR. The loose barcode 
label matched the barcode labels on the transport tubes and the Shipping Box. FEs recorded all 
vacutainer tubes that were collected and identified all difficulties during blood draw or processing on 
the manifest as well as in the tablet. The barcode-labelled manifest was designed to be scanned on 
arrival at LCBR to associate it with an individual respondent’s transport tubes.  
 
3.3.3 Shipment of Samples 
 
Immediately before shipment, FEs removed two cold packs from the freezer, sandwiched the transport 
tubes between them, enclosed the sandwich within the Styrofoam Box, placed the manifest on top of 
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the Styrofoam Box, sealed the cardboard Shipping Box around it, put the cardboard Shipping Box inside 
the Tyvek envelope, applied a pre-printed FedEx shipping label to the envelope, carried it to a FedEx 
office, and handed it to a FedEx representative (in person) for Priority Overnight shipment to LCBR with 
arrival the following morning.  FEs were not permitted to leave shipments at unattended FedEx drop 
boxes.  
 
When overnight shipment was impossible, FEs noted this on the manifest and held unboxed transport 
tubes in a refrigerator approved for biological specimens or cooler with enough cold packs to keep them 
chilled at 4⁰ C overnight without risk of freezing (or thawing), as is possible on wet or dry ice. The 
transport tubes were packaged and shipped the next day using freshly frozen cold packs. 
 
3.3.4 Receipt of Samples at LCBR 
 
LCBR technicians specifically trained for Add Health Wave V received and immediately processed 
samples each morning. They unpacked the shipping boxes one at a time, evaluated the volume and 
quality of each transport tube, and entered them into a custom-made laboratory information 
management system (LIMS) program. 
 
After re-centrifuging the serum samples for renal biomarker assays at 4° C for 10 min at 30,000 g, the 
technicians aspirated the supernatant, discarded all remaining precipitate, transferred the aspirate to 
pre-labelled tubes, and placed them in a biospecimen refrigerator for archival (in 1 ml aliquots at -80° C) 
or assay (500 ul aliquot). The LCBR technicians entered all aliquot information into the LIMS system. 
 
Samples for the creatinine assay were transferred to a pre-labelled tube for a 5-10-minute cold 
transport via a daily 3:00 pm courier to Pathology and Laboratory Medicine, in the University of 
Vermont Medical Center (UVMMC) for analysis. A separate 200 µl aliquot of serum was made for the 
cystatin C assay, which was run in-house at LCBR. This sample was kept chilled until the time of the 
assay. All assays were performed on the same day that the samples arrived at LCBR. 
 
4. Assay and Internal Quality Control 




Creatinine is a waste product derived from the normal breakdown of muscle in the body. As it is 
produced, it is filtered through the glomeruli of the kidneys. Serum creatinine concentrations are 
therefore instrumental in determining normal kidney function and can be increased in acute or chronic 
renal failure, urinary tract obstruction, reduced renal blood flow, shock, dehydration, and 
rhabdomyolysis. 
 
4.1.2 Colorimetric Assay Protocol 
 
All creatinine assays were run on the same day of sample arrival at LCBR using an Ortho VITROS 5600 
Integrated System (Ortho Clinical Diagnostics, Raritan, NJ) and VITROS Chemistry Products CREA slides, 
Add Health is a program project directed by Kathleen Mullan Harris and designed by J. Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris at the 
University of North Carolina at Chapel Hill, and funded by grant P01-HD31921 from the Eunice Kennedy Shriver National Institute of Child Health and 
Human Development, with cooperative funding from 23 other federal agencies and foundations. Information on how to obtain the Add Health data files is 
available on the Add Health website (http://www.cpc.unc.edu/addhealth). 
12 | P a g e   
i.e. multilayered, analytical elements coated on a polyester support (see Exhibit 4). Serum from venous 
blood collected using the SST vacutainer tubes was introduced into the VITROS system by placing sample 
vials holding 500 µl of serum into an automatic sampling tray, after which all processes were 
automatically performed and results output by the VITROS system.  
 
The VITROS system read barcodes on the vials to automatically determine which assays to run. In 
addition to creatinine, other assays were run from the same serum sample, including total cholesterol, 
high-density lipoprotein cholesterol, triglycerides, and glucose. Only the creatinine assay is described 













Exhibit 4. Ortho-Vitros CREA slide 
 
Upon introduction of each vial into the analyzer, 40 µl of serum was aspirated, deposited onto a CREA 
slide for analysis, and evenly distributed by the spreading layer to the underlying layers. Creatinine 
diffused to the reagent layer, where it was hydrolyzed to creatine in the rate-determining step. The 
creatine was converted to sarcosine and urea by creatine amidinohydrolase. The sarcosine, in the 
presence of sarcosine oxidase, was oxidized to glycine, formaldehyde, and hydrogen peroxide. The final 
reaction involved the peroxidase-catalyzed oxidation of a leuco dye to produce a colored product3. 
 
Following the addition of the sample, the slide was incubated. During the initial reaction phase, 
endogenous creatine in the sample was oxidized. The resulting change in reflection density at a 
wavelength of 670 nm was measured at 2 time points, 5 minutes apart. The difference in reflection 
density was determined using the software-resident two-point rate math model and was proportional to 
the concentration of creatinine present in the sample. The specific reaction scheme is listed in Exhibit 5. 
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Exhibit 5. Creatinine Assay Reaction Scheme 
 
Once the assay was carried out, the reflected light output was compared to a standard curve generated 
by the use of a VITROS Chemistry Products Calibrator Kit 1 (Ortho Clinical Diagnostics, Raritan, NJ). The 
concentrations were output to a Sunquest computer system (Sunquest Information Systems, Tucson AZ) 
that linked the UVMMC data with LCBR’s LIMS system. 
 
The VITROS 5600 system’s dynamic reporting range of the creatinine assay was from 0.05 – 14.0 mg/dL. 
When concentrations exceeded the upper limit, the VITROS system automatically diluted the samples 
1:2 with a VITROS Chemistry Products FS Diluent Pack 2 (Ortho Clinical Diagnostics, Raritan, NJ) until the 
concentrations were within range. Any dilutions were reported along with the creatinine concentrations 
in the assay results. Dilutions and creatinine concentrations that accounted for the reflexive dilutions via 
multiplication by the dilution factor were reported simultaneously.  The final creatinine concentrations 
(H5CREAT) ranged from 0.36 to 14.57 mg/dL. 
 
4.1.3 Internal Quality Control 
 
The Ortho-VITROS system was maintained daily by cleaning machine components, replacing all reagents, 
and running known quality control samples (Ortho Clinical Diagnostics, Raritan, NJ). Internal quality 
controls consisted of VITROS Performance Verifier I, which was typically 0.70-1.0 mg/dL creatinine, and 
VITROS Performance Verifier II, which was typically 5.0-6.0 mg/dL creatine, depending on the specific lot 
used.  
 
The values assigned to the VITROS Chemistry Products Calibrator Kit 1 for creatinine are traceable to a 
Gas Chromatography Isotope Dilution Mass Spectrometry (GC/IDMS) method 4 and National Institute of 
Standards and Technology (NIST) SRM® 914 creatinine standard reference material. 
 
In addition to the daily quality control, LCBR used two pools of samples from twenty normal donors (US 
Biologicals, Salem, MA) in longitudinal quality control analyses. One pool was an EDTA plasma normal 
donor pool (Lot #E050115). The other pool was a serum normal donor pool (Lot #S042715).  LCBR 
periodically assayed both pools over the course of Wave V. The plasma and serum creatinine 
concentration means and coefficients of variation based on those assays were 0.92 mg/dL (2.78%) and 
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0.95 mg/dL (2.17%), respectively. When creatinine concentrations exceeded acceptable parameters, the 
Ortho-VITROS system was investigated and repaired.  
 




Cystatin C is a non-glycosylated 13-kDa protein and is a member of the cystatin superfamily of cysteine 
protease inhibitors. Compared to serum creatinine, the level of serum cystatin C is not significantly 
affected by age, sex, race, or muscle mass.5 In addition, cystatin C is almost freely filtered through the 
glomerular membrane and then nearly completely reabsorbed and degraded by the proximal tubular 
cells. Therefore, serum levels of cystatin C are almost exclusively determined by the glomerular filtration 
rate (GFR), making cystatin C an excellent indicator for GFR.6 
 
4.2.2 Colorimetric Assay Protocol 
 
All cystatin C assays were run on the same day as sample arrival using a Siemens BNII / BN Prospec 
System (Siemens Healthcare Diagnostic Products GmbH, Marburg, Germany) and a cystatin C specific 
particle enhanced immunonephelometric assay. In this assay, polystyrene particles coated with specific 
antibodies to cystatin C were aggregated when mixed with Add Health serum samples containing 
cystatin C. These aggregates scattered a beam of light that was passed through the sample. The intensity 
of the scattered light was proportional to the concentration of the respective protein in the sample. The 
result was then evaluated by comparison with a standard of known concentration.7 Serum from venous 
blood collected using the SST vacutainer tubes was introduced into the Siemens system by placing 
sample vials holding 200 µl of serum into an automatic sampling tray, after which all processes were 
automatically performed and results output by the Siemens system. 
 
The Siemens system read barcodes on the vials to automatically determine which assay to run. Upon 
introduction of each vial into the analyzer, 40 μl of serum was aspirated and used for the assay. All 
samples were automatically diluted 1:100 with N diluent OUMT65 (Siemens Healthcare, Newark, DE). 
 
The Siemens system’s dynamic reporting range of the cystatin C assay was determined by a generated 
reference curve and multi-point calibration using two control level reagents and a Protein Standard. N 
Cystatin C Control Level 1 and 2 were calibrated to protein standard preparations of Siemens Healthcare 
Diagnostics Products GmbH and were lot dependent. Typical values (and coefficient of variation) were 
0.9 mg/L (2.5%) for Control 1 and 1.8 mg/L (2.3%) for Control 2.  Serial dilutions of the N Protein 
Standard UY were automatically prepared by the Siemens system and compared to the reference curve. 
The typical reporting range was between 0.25-8.1 mg/L using a sample dilution of 1:100. When sample 
concentrations exceeded the upper limit, the Siemens system automatically diluted the samples with 20 
μl of N diluent solution until the concentrations were within range. Dilutions and cystatin C 
concentrations that accounted for the reflexive dilutions via multiplication by the dilution factor were 
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4.2.3 Internal Quality Control 
 
The Siemens system was maintained daily by inspecting all tubing, syringes, and connections for leaks, 
cracks, or contamination. N diluent solution, reaction buffers, and wash solutions were also changed 
daily.  
 
N Cystatin C Control Levels 1 and 2 were assayed after each establishment of a reference curve, the first 
use of a reagent vial as well as with each run of samples. LCBR also ran EDTA and serum controls as 
specimen samples each time a new standard curve was established. In addition to the daily quality 
control, LCBR used two pools of samples from twenty normal donors (US Biologicals, Salem, MA) in 
longitudinal quality control analyses. One pool was an EDTA plasma normal donor pool (Lot #E050115). 
The other pool was a serum normal donor pool (Lot #S042715).  LCBR periodically assayed both pools 
over the course of Wave V. The plasma and serum cystatin C concentration mean and coefficient of 
variation based on those assays was 0.713 mg/L (7.41%) and 0.654 mg/L (8.10%) before International 
Federation of Clinical Chemistry and Laboratory Medicine (IFCC) standardization and 0.840 mg/L (3.68%) 
and 0.79 mg/L (3.85%) after IFCC standardization (see sections 4.2.4-4.2.5).  When cystatin C 




In 2010, The IFCC Working Group for the Standardization of Cystatin C (WG-SCC), in collaboration with 
the Institute for Reference Materials and Measurements (IRMM), announced the availability of the new 
certified cystatin C reference material, ERM-DA471/IFCC.8 Although use of this reference standard had 
progressed in Europe since the announcement, only recently had Food and Drug Administration 
approved it for use in the United States.9 Following approval, Siemens notified LCBR in March 2018 that 
it was discontinuing the pre-IFCC standardization N Latex Cystatin C Reagent Assay Kit because the FDA 
had approved the ERM-DA471/IFCC reference material. Thereafter, assay kits using the post-IFCC 
standardization N Latex Cystatin C became available to U.S. users for measuring IFCC-calibrated cystatin 
C concentrations. Between April 2016 and November 2017, LCBR had already run 1940 Add Health 
respondent samples, but did not have enough pre-IFCC assay kits to process the remainder. Moreover, 
Siemens did not have any more pre-IFCC assay kits. 
 
4.2.5 Inter-conversion of Pre- & Post-IFCC Standardization of Cystatin C Concentrations 
 
Four samples were therefore selected at random from those 1940 respondents with pre-IFCC 
standardization cystatin C concentrations within each of 24 strata defined by race/ethnicity (non-
Hispanic white; non-Hispanic black; Hispanic; other), sex (male; female), and cystatin C concentration 
ventile (1st; 2nd-19th; 20th), i.e. < 0.5, 0.5-0.8, and > 0.8 mg/L. Collectively, the stratified, random sample 
included 4 × 24 = 96 respondents among whom archived 1 ml frozen serum vials were thawed, pre-IFCC 
standardization cystatin C concentrations were re-assayed in 40 μl , all pre-IFCC reagents and standards 
were replaced with the post-IFCC set, the Siemens BNII system was recalibrated, post-IFCC 
standardization cystatin C concentrations were assayed in another 40 μl maintained at 4℃ in the 
interim, and the remaining 920 µl of serum were re-archived. The association between the post- and 
pre-IFCC standardization cystatin C concentrations (Exhibit 6) was modeled using Deming regression,10,11 
i.e. post-IFCC cystatin C = α + β × pre-IFCC cystatin C (Pearson r = 0.98). Estimates of α, β and their 95% 
CIs were 0.003 (-0.057, 0.063) and 1.164 (1.077, 1.251). Because α was small and no different from zero, 
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β was used to convert all pre- to post-IFCC cystatin C concentrations via multiplication and converted 
concentrations were flagged accordingly (H5CYSCAJ=1).  The final post-IFCC cystatin C concentrations 
(H5CYSC) ranged from 0.34 to 8.08 mg/L. 
 
Exhibit 6. Plot of Post- Versus Pre-IFCC Standardized Cystatin C Concentrations (mg/L) 
 




Within a race/ethnicity- and sex-stratified random sample of 103 Add Health respondents among whom 
venous blood was collected twice, on average 14.3 (95% confidence interval: 13.0-15.5) days apart, 
typically by the same FE and at approximately the same time of day, the reliability of creatinine (mg/dL) 
and cystatin C (mg/dL) was estimated as an intra-class correlation coefficient (ICC, 95% confidence 
interval).  The resulting estimates (Exhibit 7) suggest that the home exam venous blood yielded highly 
reliable creatinine and cystatin C concentrations.   
 
Measure n ICC 95% CI 
Creatinine (mg/dL)  103 0.93 (0.91, 0.96) 
Cystatin C (mg/L) 103 0.86 (0.81, 0.91) 
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6. Constructed Measures 
 
6.1. Estimated Glomerular Filtration Rate (eGFR) According to NIDDK CKD-EPI Guidelines 
[H5GFRCRE; H5GFRCYC; H5GFRCC] 
 
The glomerular filtration rate (GFR, ml/min/1.73 m2) was estimated in three different ways using either 
the creatinine concentration, the cystatin C concentration or both concentrations.  Each was estimated 
using the following National Institute of Diabetes and Digestive and Kidney Diseases Chronic Kidney 
Disease Epidemiology Collaboration (NIDDK CKD-EPI) equations:1 
 
• Based on creatinine (H5GFRCRE) 
 
eGFRcr  = 141  ×  min(Scr/κ, 1)α  ×  max(Scr/κ, 1)−1.209  ×  0.993Age   
[× 1.018 if female]  [× 1.159 if black]  
 
where:  
o Scr = creatinine concentration (mg/dL) 
o κ = 0.7 (female) or 0.9 (male) 
o α = −0.329 (female) or −0.411 (male) 
 
 
• Based on cystatin C (H5GFRCYC) 
 
eGFRcys = 133 × min(Scys/0.8, 1)-0.499  ×  max(Scys/0.8, 1)-1.328  ×  0.996Age  
[× 0.923 if female]   
 
where:   
o Scys = cystatin C concentration (mg/L) 
 
 
• Based on creatinine and cystatin C (H5GFRCC) 
 
eGFRcr_cys = 135  ×  min(Scr/κ, 1)α  ×  max(Scr/κ, 1)−0.601  ×   
min(Scys/0.8, 1)-0.375  ×  max(Scys/0.8, 1)-0.711  ×  0.995Age   
[× 0.969 if female]  [× 1.080 if black] 
 
where:  
o Scr = creatinine concentration (mg/dL) 
o Scys = cystatin C concentration (mg/L) 
o κ = 0.7 (female) or 0.9 (male) 
o α = −0.248 (female) or −0.207 (male) 
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6.2. Classifications of eGFR According to KDIGO Guidelines [H5CGFRKR; H5CGFRKY; H5CGFRKC] 
 
The following classification variables were constructed according to the Kidney Disease: Improving 
Global Outcomes (KDIGO) guidelines:2 
 
• Based on creatinine [H5CGFRKR] 
• Based on cystatin C [H5CGFRKY] 
• Based on both creatinine and cystatin C [H5CGFRKC] 
 




(ml/min/1.73 m2) KDIGO Class 
1 ≥ 90 Normal/High (G1) 
2 60-89 Mildly decreased (G2) 
3 45-59 Mildly to moderately decreased (G3a) 
4 30-44 Moderately to severely decreased (G3b) 
5 15-29 Severely decreased (G4) 
6 < 15 Kidney failure (G5) 
   
Exhibit 8. KDIGO Classification of eGFR based on Creatinine, Cystatin C, or Both 
 
6.3. Clinical Classifications of eGFR 6.3 [H5CGFRCR; H5CGFRCY; H5CGFRCC] 
 
The following classification variables were constructed: 
 
• Based on creatinine [H5CGFRCR] 
• Based on cystatin C [H5CGFRCY] 
• Based on both creatinine and cystatin C [H5CGFRCC] 
 




(ml/min/1.73 m2) Clinical Class 
1 ≥ 60 Neither 
2 15-59 Chronic kidney disease (CKD) 
3 < 15 End-stage kidney disease (ESKD) 
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7. The Renal Function Data File (brenal5.xpt) 
7.1. Structure 
 
The structure of the disseminated renal function data file is flat.  This means that it is a respondent-level 
data file, where each respondent has one and only one record.  The respondent’s identifying number 




The renal function data file includes the variables below, which are described in the corresponding 
codebook documentation that also contains frequencies.  
 
Variable Name Variable Description 
AID Respondent Identifier 
H5CREAT Creatinine (mg/dL) 
H5CYSC Cystatin C (mg/L) 
H5CYSCAJ Flag: Cystatin C converted from pre- to post-IFCC standardization 
H5GFRCRE eGFR Creatinine (ml/min/1.73 m2) 
H5GFRCYC eGFR Cystatin C (ml/min/1.73 m2) 
H5GFRCC eGFR Creatinine & cystatin C (ml/min/1.73 m2) 
H5CGFRKR eGFR Creatinine classification according to KDIGO  
H5CGFRKY eGFR Cystatin C classification according to KDIGO  
H5CGFRKC eGFR Creatinine & cystatin C classification according to KDIGO  
H5CGFRCR eGFR Creatinine clinical classification 
H5CGFRCY eGFR Cystatin C clinical classification 
H5CGFRCC eGFR Creatinine & cystatin C clinical classification 
H5Q045D Q045d Ever diagnosed with kidney disease or failure 
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